CTLA4 and neoplasm: Interestingly, they also showed that only the administration of anti-CTLA-4 before Doxil® could present synergic efficacy (i.e., tumor growth delay = 161.32% vs. 102.56% and 48.51% for concomitant and Doxil® before anti-CTLA-4 administration, respectively), highlighting the importance of the combination modalities (i.e., duration, sequence, dosing interval, and dose).